Background: Satraplatin is an oral platinum analog with demonstrated activity in a range of malignancies. The current study was designed to evaluate the effect of varying degrees of renal impairment on the safety and pharmacokinetics (PKs) of satraplatin.
before study entry (6 weeks for nitrosourea or mitomycin). Other eligibility criteria included age ‡18 years; an Eastern Cooperative Oncology Group performance status less than or equal to two; adequate hematopoietic function (absolute neutrophil count ‡1500/ll, platelet count ‡100 000/ll, and hemoglobin ‡9 g/dl); adequate hepatic function [total bilirubin £1.5 · the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) £3.0 · ULN (AST or ALT £5 · ULN if caused by liver metastasis)]; and measurable or evaluable disease. Exclusion criteria included any of the following: symptomatic or active brain metastasis; serious intercurrent illness incompatible with the study; and cancer that had failed to respond, at least transiently, to previous platinumcontaining regimens. Written informed consent was obtained according to federal and local institutional guidelines. The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the applicable guidelines on good clinical practice.
study design
The study was carried out at Memorial Sloan-Kettering Cancer Center (New York, NY), MD Anderson Cancer Center (Houston, TX), Indiana University Simon Cancer Center (Indianapolis, IN), and University of Wisconsin Comprehensive Cancer Center (Madison, WI). Eight patients per cohort were stratified into four treatment groups based on renal function (Table 1) . Renal function was estimated based on the calculated creatinine clearance (CrCl), during the screening period, using the Cockcroft-Gault formula [14] .
A treatment cycle was defined as 35 days. Satraplatin was administered orally at a dose of 80 mg/m 2 /day on days 1-5 of each cycle, followed by a 30-day follow-up period. Each patient was premedicated with a 5-hydroxytryptamine-3 receptor antagonist antiemetic agent 1 h before study drug dosing each day on days 1-5 of every cycle. All patients were instructed to fast from 10:00 p.m. of the evening before day 1 and day 5 of cycle 1 until 2 h postdose. Patients were admitted to the research study unit for $24 h on days 1 and 5 of cycle 1. Dosing for cycle 1 was administered in the research study unit, while dosing for all subsequent cycles were self-administered on an outpatient basis.
Restaging radiographic evaluations occurred after every two cycles. Patients could remain on treatment until the time of disease progression. Patients with disease that remained stable or improved could continue to receive additional cycles of satraplatin.
Criteria were defined for individual dosing delays and dose modification as well as for cohort dose deescalation and stopping rules. The determination of dose-limiting toxicity (DLT) for purposes of assessing dose deescalation was defined as follows using the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events version 3.0: grade 4 thrombocytopenia >4 days, grade 4 neutropenia >7 days, febrile neutropenia, any drug-related grade 3 or 4 nonhematologic toxicity excluding nausea, vomiting, and alopecia. If two of the first six patients enrolled into a cohort experienced a drug-related DLT during cycle 1, subsequent patients in that cohort and all patients in cohorts with more severe renal impairment were to be treated with an initial satraplatin dose of 60 mg/m 2 . If two of six patients in a reduced dose cohort (60 mg/m 2 ) experienced a DLT, enrollment to that cohort and all cohorts with patients with more severe renal impairment was to be stopped.
Treatment of individual patients experiencing grade 2 nonhematologic toxic effects was held until improvement to £grade 1 and resumed at the next cycle at the original dose. Patients experiencing grade 3 or 4 nonhematologic toxic effects required interruption of treatment until improvement to £grade 1. Treatment could then be restarted at the next cycle with a dose reduction by 20 mg/m 2 /day for the 5-day dosing period. Patient experiencing grade 3 or 4 hematologic toxic effects required interruption of treatment until improvement to £grade 2. If the toxicity resolved within 2 weeks, treatment could be resumed at the original dose, while toxic effects taking longer to resolve necessitated a dose reduction by 20 mg/m 2 /day for the 5-day dosing period. Patients developing recurrent grade 3 or 4 hematologic toxic effects, despite a dose reduction, were removed from study.
baseline and treatment assessments
Medical histories were recorded and physical examinations were carried out before initiation of each cycle of therapy. Hematology evaluations were carried out at screening and before initiation of each cycle, weekly, and at the end of study. Serum chemistry evaluations were carried out at screening, before initiation of each cycle, and at the end of study. Prothrombin time and partial thromboplastin time were carried out at screening and at the end of study. Serum b-human chorionic gonadotropin testing for pregnancy was carried out at the screening visit and before initiation of each cycle. Radiologic studies for disease assessment were conducted at baseline and after every other cycle. Tumor response was assessed according to RECIST [15] .
PK sampling and bioanalytic methodology
On day 1 and day 5 (cycle 1 only), blood samples for PK analysis were obtained predose (time 0, within 15 min before dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 h postdose. On day 1 (cycle 1 only), four urine samples were collected for PK assessment predose and during the intervals of 0-6 h, 6-12 h, and 12-24 h postdose.
Blood samples (7 ml) were collected in vials containing ethylenediaminetetraacetic acid via an indwelling venous catheter and cooled immediately on ice and then centrifuged at 2000 g for 10 min under refrigeration (4°C) within 30 min of collection. Plasma ultrafiltrate (PUF) was collected from the separated plasma using Millipore Centrifree YM-30 ultrafiltration devices (Millipore, Billerica, MA). Both plasma and PUF were obtained from the same 7-ml blood sample. Plasma samples were analyzed for platinum from satraplatin (Covance Laboratories, Madison, WI) by inductively coupled plasma mass spectrometry after dilution with 0.005% Triton X-100 in 0.5% nitric acid. PUF samples were analyzed for platinum from satraplatin by inductively coupled plasma mass spectrometry after dilution with 1% nitric acid. The samples were analyzed without predigestion directly against matrix-matched solutions. Intensity as counts per second from platinum, mass 195, were measured. Terbium, mass 159, was used as an internal standard. Results were calculated from the net intensity ratio of platinum to internal standard. Urine samples were analyzed for platinum using a similar analytic technique.
PK analyses
PK parameters were determined for platinum in plasma, PUF, and urine and were calculated using actual plasma and PUF concentration-time data and noncompartmental techniques (WinNonlinÒ Professional Network Edition, version 4.0.1; Pharsight Corp., Mountain View, CA). The following parameters were recorded: C max , the maximum concentration observed during the sampling period; C trough , trough concentration; T max , the time at which C max was observed; AUC 0-24 , the area under the concentration-time original articles
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curve from time 0-24 h; k z , the elimination rate constant obtained from the linear regression of the natural logarithmic-transformed concentration versus time data in the terminal phase; t 1/2 , the terminal elimination halflife calculated as t 1/2 = ln(2)/k z .
The following PK parameters were calculated for total platinum in urine for day 1 only: A e , the cumulative amount of the platinum excreted in the urine between time 0 and t last ; % A e , the percent of platinum recovered unchanged in urine from time 0 to the last measurable urine concentration calculated as % A e = (A e /Dose) · 100. Dose of platinum was calculated as 39% of actual satraplatin received dose; CL r , renal clearance calculated as CL r = A e /PUF AUC 0-last .
statistical analysis
Descriptive statistics were used to summarize the PK parameters for each renal function group. Toxic effects were summarized in a tabular manner for all treatment-related events. Previous studies evaluating satraplatin in subjects with normal renal function suggested that the coefficient of variation for day 5 AUC 0-24 is <25%. For design of the current study, an assumption was made that the standard deviation of the log-normal distributed PK parameter was 0.2 and the log-scale PK parameter increment with decreasing CrCl was 0.14 (e.g. geometric mean AUC 0-24 ratio of groups 2 : 1, 3 : 2, or 4 : 3 is 1.15). Statistical significance of PK parameter differences among renal function groups was assessed based on a two-sided test at the 5% significance level for the log-transformed parameter regression on baseline CrCl. Therefore, the study was designed to enroll at least six assessable patients in each renal impairment group, which had at least 80% power to detect a statistically significant effect of renal function on the PK parameters if the true mean AUC 0-24 increased at least 15% compared between each renal impairment group (mild renal impairment compared with normal function, moderate compared with mild, and severe compared with moderate).
Log-transformed AUC 0-24 , C max , and C trough of total plasma and PUF platinum following the day 1 and day 5 doses were plotted in scatter plot displays versus CrCl. A regression model fit to the log-transformed parameters dependent on CrCl was fit and statistical significance of the slope was determined. Table 2 ). The target accrual of eight patients was met in each renal function group. The most common diagnoses were bladder cancer (n = 9), prostate cancer (n = 5), breast cancer (n = 4), and colorectal cancer (n = 4).
drug delivery and treatment discontinuation
The median number of cycles completed for all patients was two (range: one-nine cycles). Eleven patients experienced Across all renal function groups, a total of 23 patients (72%) discontinued treatment due to disease progression. Other reasons for treatment discontinuations were: three patients in Group 3 due to adverse events (abdominal pain, infection, and thrombocytopenia/anemia), two patients in Group 2 due to death (attributed to disease progression), two patients in Group 3 due to voluntary withdrawal, and two patients due to investigator judgment (one patient each in Group 1 and Group 4).
adverse events
There were no DLTs and no cohorts required dose deescalation. Table 3 provides a summary of all treatment-related adverse events, by grade, for each renal function group. Most of the adverse events were grade 1-2. The most commonly observed treatment-related adverse events were fatigue (20, 63%), nausea (18, 56%), diarrhea (17, 53%), anorexia (15, 47%), constipation (12, 38%), vomiting (9, 28%), anemia, dyspnea, and thrombocytopenia in eight patients each (8, 25%). One patient experienced a grade 4 adverse event that was at least possibly related to drug, failure to thrive, described in more detail below.
Seventeen patients experienced a serious adverse event of which 4 patients were assessed as at least possibly related to study drug: abdominal pain, hypotension, infection without neutropenia, and pyrexia. There was one death on study in a patient that experienced grade 4 failure to thrive. This patient was a 50-year-old man with metastatic colon cancer enrolled in Group 2. On day 15 of cycle 1, the patient presented with grade 4 pain (not attributed to study drug) and grade 4 failure to thrive (at least possibly attributed to study drug). He was determined to have disease progression and died on day 21. pharmacokinetics A summary of PK parameters on day 1 by treatment group is presented in Table 4 and Figure 1 . Mean C max and AUC 0-24 for Group 2 were comparable with Group 1 for plasma platinum and PUF platinum on day 1. On day 1, mean C max and AUC 0-24 for Group 3 increased by 37% and 39%, respectively, for plasma platinum and by 35% and 44%, respectively, for PUF platinum compared with Group 1. Mean C max and AUC 0-24 for Group 4 increased by 58% and 59%, respectively, for plasma platinum and by 103% and 149%, respectively, for PUF platinum compared with Group 1. The k z and t 1/2 for patients on day 1 were also reported; however, since the true half-life of platinum on day 5 is over 200 h, the sample collection of 24 h was not sufficient to characterize the half-life based on day 1 platinum concentrations. The urine platinum PK parameters are presented in Table 5 . On day 1, the mean CL r for Group 2, for Group 3, and for Group 4 decreased by 20%, 49%, and 68%, respectively, compared with Group 1.
A summary of PK parameters on day 5 by treatment group is presented in Table 6 and Figure 1 . Mean C max , AUC 0-24 , and C trough for Group 2 were comparable with Group 1 for plasma platinum and PUF platinum on day 5. On day 5, mean C max , AUC 0-24 , and C trough for Group 3 increased by 27%, 27%, and 22%, respectively, for plasma platinum and by 58%, 59%, and 70%, respectively, for PUF platinum compared with Group 1. Mean C max , AUC 0-24 , and C trough for Group 4 increased by 327%, 35%, and 39%, respectively, for plasma platinum and by 139%, 263%, and 351%, respectively, for PUF platinum compared with Group 1. The day 5 t 1/2 for both plasma platinum and PUF platinum was not significantly altered in each group compared with Group 1. original articles
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Regression analyses of day 1 and day 5 plasma and PUF PK parameters (C max , AUC 0-24 , and C trough of day 5) demonstrated that these parameters increased in patients with lower CrCl. Trends for each parameter were all statistically significant (P < 0.05). The results of the regression analysis for AUC 0-24 are presented in Table 7 .
antitumor activity
Of the 24 patients with measurable disease who completed at least two cycles of treatment and underwent restaging radiographic evaluations, one patient (4%) achieved a partial response. This patient had breast cancer metastatic to the lungs and paravertebral region. She had received multiple prior systemic treatment regimens, but no prior platinum-based therapy, and remained on treatment for nine cycles. An additional six patients (19%) achieved stable disease for at least 2 months as their best response (including patients with ocular melanoma, colon cancer, non-small-cell lung cancer, bladder cancer, and two patients with prostate cancer). Progressive disease was the best response in the remaining 10 patients (42%).
discussion
This study demonstrated an increased exposure to plasma platinum and PUF platinum in patients with moderate to severe renal impairment (i.e. CrCl values below 50 ml/min). The increased exposure was based on the measured increase in plasma and PUF platinum concentrations. Notably, the measured platinum represents the sum of all platinum-containing moieties in plasma or PUF and concentrations of these individual molecules were not measured separately. Prior biotransformation studies in human subjects have demonstrated the presence of six platinum peaks in plasma PUF samples after administration of satraplatin with the cytotoxicity profile of the three major metabolites very close to that of the parent drug [8, 9] . In the current study, it is not known what PK changes, if any, occurred in the individual biologically active platinum moieties. The PK parameters for satraplatin in patients with normal renal function and mild renal impairment, in the current study, were comparable to other published PK studies of satraplatin in patients with normal renal function [16] . In addition, similar to other published PK studies, the interpatient variability was not found to be significant. The safety profile observed in this study was not unexpected, given the patient population and known toxic effects of the study drug. Patients with moderate and severe renal impairment tended to experience slightly more fatigue, diarrhea, vomiting, and anemia compared with patients in the normal or mildly impaired renal function groups. However, it is unclear if these differences were due to the more severe state of renal disease or due to the higher platinum exposure seen in Table 5 . Mean (6SD) urine platinum pharmacokinetic parameters on day 1 Urine PK parameters (unit) Twenty-four-hour urine samples were not collected from two subjects in Group 2, one subject in Group 3, and two subjects in Group 4. SD, standard deviation; PK, pharmacokinetic. Table 6 . Mean (6SD) plasma platinum and PUF platinum pharmacokinetic parameters on day 5
Plasma platinum C max (ng/ml) 494. A disconnect between the PKs and pharmacodynamics of another platinum drug, oxaliplatin, has also been demonstrated in patients with impaired renal function [17] . In a phase I study of oxaliplatin in patients with renal impairment, the lack of association between increased platinum exposure and adverse events in patients with worse renal function was attributed to the complex mixture of both active and inactive platinum species measured by the total platinum assay. The investigators hypothesized that the active drug was cleared rapidly from PUF via mechanisms independent of renal function (e.g. protein binding, tissue distribution, cellular sequestration, and reactions with plasma constituents), whereas the majority of unbound platinum in the form of inactive, low-molecular weight conjugates, was cleared by glomerular filtration. Whether or not such a mechanism explains the lack of correlation between increased exposure and toxicity with satraplatin cannot be determined from the current study.
An increase in exposure with decreasing CrCl also raises the possibility of a saturable mechanism for elimination and distribution. However, due to the estimated half-life of platinum exceeding 200 h, sample collection in the current study was insufficient to accurately estimate the AUC 0-N . Consequently, the possibility of a saturable mechanism or mechanisms of elimination and distribution cannot be evaluated.
A large proportion (38%) of patients enrolled in this study had advanced urothelial carcinoma. While this represents an atypical distribution of diagnoses for a phase I study, this distribution likely reflects both the patient populations of the treating investigators and the frequency of renal dysfunction in patients with urothelial cancer [13] . In the current study, satraplatin was associated with negligible antitumor activity, with a single durable partial response in a patient with platinum-naive breast cancer. However, this patient population was heavily pretreated, and most patients had received prior platinum therapy.
Satraplatin has been evaluated in prostate cancer in an international randomized phase III trial [Satraplatin and Prednisone Against Refractory Cancer (SPARC)] that compared satraplatin with placebo in patients with castrationresistant prostate cancer who had disease progression despite one prior chemotherapy regimen [10] . Patients on the SPARC trial were randomized 2 : 1 to receive oral satraplatin 80 mg/m 2 /day on days 1-5 of a 35-day schedule plus prednisone versus placebo plus prednisone. Treatment with satraplatin was associated with a significant reduction in pain and a 33% reduction [hazard ratio (HR) = 0.67; 95% confidence interval (CI) 0.57-0.77; P < 0.001] in the risk of disease progression. However, no difference in overall survival was seen between the satraplatin and placebo arms (HR = 0.98; 95% CI 0.84-1.15; P = 0.80). Based on these results, satraplatin did not receive regulatory approval by the US Food and Drug Administration.
Despite the outcome of the SPARC trial, the phase III data clearly demonstrate that satraplatin has clinical activity in a subset of patients. Current efforts to further develop this agent are focused on exploring potential predictive biomarkers. For example, a study at the NCI (NCT00634647) is evaluating the association of ERCC1 gene polymorphisms with clinical outcomes in men with prostate cancer treated with satraplatin. Another ongoing pilot trial, at Mount Sinai School of Medicine, will determine whether a gene signature of 'BRCAness', derived from metastatic prostate cancer biopsy tissue, correlates with response to treatment with satraplatin in men with castration-resistant disease (NCT01289067).
In summary, in patients with advanced solid tumors treated with satraplatin, renal impairment decreases plasma and PUF platinum clearance and increases systemic platinum exposure. However, a corresponding increase in toxic effects was not observed. Based on these findings, and the possible mixture of both active and inactive platinum species measured by the total platinum assay, satraplatin dose reductions in patients with renal impairment are not definitively indicated.
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